Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton(Madrigal Pharmaceuticals (United States)), Atif Zaman, Alexander Kuo(Cedars-Sinai Medical Center), John R. Lake(University of Minnesota), Norah A. Terrault(University of Southern California), Lewis Teperman(Hofstra University), Hadas Dvory‐Sobol(Gilead Sciences (United States)), Charles Landis(University of Washington), R. S. Brown(Columbia University Irving Medical Center), Paul Y. Kwo(Palo Alto University), Phillip S. Pang(Gilead Sciences (United States)), Hugo E. Vargas(Mayo Clinic in Arizona), Andrew J. Muir(Duke University), K. Rajender Reddy(Hospital of the University of Pennsylvania), Eugene R. Schiff(University of Miami), Nezam H. Afdhal(Beth Israel Deaconess Medical Center), Michael P. Curry, Surakit Pungpapong(Jacksonville College), Kevin Korenblat(Washington University in St. Louis), Mark Sulkowski(Johns Hopkins University), Gregory T. Everson(ColdQuanta, Inc., DBA Infleqtion (United States)), Kymberly D. Watt(Mayo Clinic), Jacqueline G. O’Leary(Veterans Health Administration), Robert J. Fontana(University of Michigan), John G. McHutchison(Gilead Sciences (United States)), Greg Everson(University of Colorado Denver), Rajender Reddy(California University of Pennsylvania), Steven L. Flamm(Northwestern University), Jill Denning(Gilead Sciences (United States)), Sarah Arterburn(Gilead Sciences (United States)), Princy Kumar(Georgetown University), Kris V. Kowdley(Liver Institute Northwest), Robert S. Brown(Cornell University), Kimberly Brown(Henry Ford Health System), Michael Fried(University of North Carolina at Chapel Hill), S. Flamm(Northwestern University), T. Brandt-Sarif(Gilead Sciences (United States)), Andrew J. Muir(Duke Medical Center), Richard Gilroy(University of Kansas)
Cited by 799
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k